📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
PGHL Declares ₹160 Interim Dividend Including ₹50 Special Dividend
Procter & Gamble Health Limited has announced a substantial interim dividend of ₹160 per equity share for the financial year 2025-26. This total payout includes a one-time special dividend of ₹50 per share, signaling a significant cash distribution to shareholders. The record date for determining eligibility is set for February 12, 2026. Shareholders must ensure their tax documents and PAN details are updated by February 10, 2026, to avoid higher TDS deductions.
Key Highlights
Declared an interim dividend of ₹160 per equity share with a face value of ₹10 each.
The payout includes a one-time special dividend component of ₹50 per share.
The record date for determining shareholder eligibility is February 12, 2026.
Standard TDS of 10% applies for resident shareholders with PAN; 20% for those without.
Submission deadline for tax exemption forms (15G/15H) is February 10, 2026.
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the record date of February 12, 2026. Existing shareholders should promptly submit tax-related declarations to the RTA by February 10 to optimize their net payout.
PGHL Q3 Net Profit Drops 14.6% to ₹77.6 Cr; Declares Massive ₹160 Interim Dividend
Procter & Gamble Health Limited (PGHL) reported a 20.7% YoY growth in revenue to ₹373.86 crore for the quarter ended December 31, 2025. Despite revenue growth, net profit declined by 14.6% YoY to ₹77.59 crore due to a significant 40% surge in total expenses, particularly in raw materials and employee benefits. To reward shareholders, the board declared a substantial interim dividend of ₹160 per share, which includes a ₹50 special dividend. The record date for this payout is February 12, 2026.
Key Highlights
Revenue from operations increased by 20.7% YoY to ₹373.86 crore from ₹309.77 crore.
Net profit for the quarter fell 14.6% YoY to ₹77.59 crore compared to ₹90.90 crore in the previous year.
Declared an interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Total expenses rose sharply to ₹269.40 crore from ₹192.04 crore in the corresponding quarter last year.
Nine-month net profit for the period ended December 2025 stands at ₹232.31 crore, up from ₹190.01 crore YoY.
💼 Action for Investors
Investors should focus on the high dividend yield offered by the ₹160 payout, while keeping a close watch on rising operating costs that impacted quarterly margins. The stock is likely to attract yield-seeking investors ahead of the February 12 record date.
PGHL Q3 Sales Up 21% to ₹368 Cr; Declares ₹160 Interim Dividend per Share
Procter & Gamble Health Limited (PGHL) reported a strong 21% year-on-year growth in sales, reaching ₹368 crores for the quarter ended December 31, 2025. The company's Profit After Tax (PAT) stood at ₹78 crores, driven by robust brand fundamentals and new product innovations like Livogen Iron Gummies. A major highlight for shareholders is the declaration of an interim dividend of ₹160 per equity share, which includes a ₹50 special dividend. This performance underscores the company's leadership in the vitamins, minerals, and supplements (VMS) category in India.
Key Highlights
Sales for the quarter ended December 31, 2025, rose 21% YoY to ₹368 crores.
Profit After Tax (PAT) for the quarter reached ₹78 crores.
Declared an interim dividend of ₹160 per share, including a one-time special dividend of ₹50.
Growth supported by new innovations including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
Strong top-line momentum maintained from the first half of the financial year 2025-26.
💼 Action for Investors
Investors should take note of the significant dividend payout and strong revenue growth as signs of a healthy cash-rich business. The stock remains a solid play in the VMS segment with high brand equity in products like Neurobion and Evion.
PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Up 20.7% YoY to Rs 373.86 Cr
Procter & Gamble Health Limited has declared a substantial interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, revenue grew 20.7% YoY to Rs 373.86 crore, although net profit declined 14.6% to Rs 77.59 crore due to higher operating expenses. The nine-month performance remains strong with a net profit of Rs 232.31 crore compared to Rs 190.01 crore in the previous year. The record date for the dividend is fixed as February 12, 2026.
Key Highlights
Declared an interim dividend of Rs 160 per equity share, including a Rs 50 special dividend
Q3 Revenue from operations rose 20.7% YoY to Rs 373.86 crore from Rs 309.77 crore
Net profit for the quarter dipped to Rs 77.59 crore from Rs 90.90 crore YoY due to increased expenses
Nine-month net profit increased to Rs 232.31 crore from Rs 190.01 crore in the corresponding previous period
Record date for dividend eligibility is February 12, 2026, with payment by March 4, 2026
💼 Action for Investors
Investors seeking high dividend yields should ensure they hold shares before the February 12 record date. While quarterly margins were pressured by costs, the overall nine-month growth and high payout ratio remain attractive for long-term holders.
PGHL Declares ₹160 Interim Dividend; Q3 Revenue Rises 20.7% to ₹373.86 Crore
Procter & Gamble Health Limited (PGHL) has declared a significant interim dividend of ₹160 per share, which includes a ₹50 special dividend. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to ₹373.86 crore. However, net profit for the quarter saw a decline of 14.6% YoY to ₹77.59 crore due to increased operational expenses. Despite the quarterly profit dip, the nine-month profit for the period ending December 2025 remains strong at ₹232.31 crore, up from ₹190.01 crore in the previous year.
Key Highlights
Declared interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Revenue from operations grew to ₹373.86 crore in Q3 FY26 from ₹309.77 crore in Q3 FY25.
Net profit for the quarter stood at ₹77.59 crore, down from ₹90.90 crore in the corresponding previous quarter.
Nine-month net profit showed healthy growth, reaching ₹232.31 crore compared to ₹190.01 crore YoY.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.
💼 Action for Investors
Investors should ensure they hold shares by the February 12 record date to benefit from the high dividend payout. While quarterly margins were pressured, the overall nine-month growth and strong dividend policy reflect a stable financial position.
PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Rises 20.7% to Rs 373.9 Crore
Procter & Gamble Health Limited (PGHL) has announced a significant interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to Rs 373.86 crore. However, quarterly net profit declined by 14.6% YoY to Rs 77.59 crore, impacted by a sharp rise in employee benefits and other operational expenses. Despite the quarterly profit dip, the nine-month performance remains robust with a 22.3% growth in net profit to Rs 232.31 crore.
Key Highlights
Declared interim dividend of Rs 160 per equity share, including a Rs 50 special dividend.
Q3 Revenue from operations grew 20.7% YoY to Rs 37,386 lakhs.
Nine-month Net Profit increased by 22.3% YoY to Rs 23,231 lakhs.
Total expenses for the quarter rose significantly to Rs 26,940 lakhs from Rs 19,204 lakhs in the previous year.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.
💼 Action for Investors
Investors should ensure they hold shares by the February 12 record date to qualify for the substantial dividend payout. While quarterly margins were pressured by higher costs, the strong nine-month growth and high dividend yield remain attractive for income-seeking investors.